Australian pharma company CSL posts strong half year profit
Shares of Australia's CSL were down on Wednesday, despite posting a 10% increase in its first half year profit
Australian pharmaceutical company CSL has post its first half profit, with a 10.1% increase following stronger drug sales.
CSL said the increase was due to stronger drug sales in the US, allowing the company to raise their full-year guidance higher range than earlier provided.
Net proft for the six months to December 31 came in at $1.2 billion on a constant currency basis, lifting from last year’s $1.1 billion.
Sales revenue for the six months to December 31 rose 8.6 per cent to $4.342 billion, and CSL raised its interim dividend to 85 US cents.
'This is a solid result and particularly pleasing given it follows a very strong comparative period,' chief executive and managing director Paul Perreault said in a statement.
CSL, Australia’s fifth-largest listed company said in a statement that it expected fiscal 2019 net profit to be around the upper end of the provided range of $1.88 billion to $1.95 billion on a constant currency basis. The majority of CSL's earnings come from influenza vaccine sales by its Seqirus division.
In October, the company's influenza vaccine for use in people six months of age and older was approved by the US Food and Drug Administration.
The company also said that demand for its plasma products were strong, and it plans to open between 30 and 35 new collection centres during the year
CSL's influenza vaccine business, Seqirus, delivered first-half earnings before interest and taxes of $300 million, compared to a full-year loss of more than $200 million three years ago, Mr Perreault said.
CSL share price
Despite the positive results, CSL Ltd shares were down 2.7% on Wednesday , at $188.44 at time of writing.
IGA, may distribute information/research produced by its respective foreign affiliates within the IG Group of companies pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the research is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, IGA accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact IGA at 6390 5118 for matters arising from, or in connection with the information distributed.
The information/research herein is prepared by IG Asia Pte Ltd (IGA) and its foreign affiliated companies (collectively known as the IG Group) and is intended for general circulation only. It does not take into account the specific investment objectives, financial situation, or particular needs of any particular person. You should take into account your specific investment objectives, financial situation, and particular needs before making a commitment to trade, including seeking advice from an independent financial adviser regarding the suitability of the investment, under a separate engagement, as you deem fit.
Please see important Research Disclaimer.
Seize a share opportunity today
Go long or short on thousands of international stocks.
- Increase your market exposure with leverage
- Get spreads from just 0.1% on major global shares
- Trade CFDs straight into order books with direct market access
Live prices on most popular markets
Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 15 mins.